The price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) closed at $1.03 in the last session, up 14.79% from day before closing price of $0.90. In other words, the price has increased by $+0.1327 from its previous closing price. On the day, 1796621 shares were traded.
Ratios:
We take a closer look at CTXR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on November 30, 2021, initiated with a Buy rating and assigned the stock a target price of $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTXR now has a Market Capitalization of 163.87M and an Enterprise Value of 143.95M.
Stock Price History:
The Beta on a monthly basis for CTXR is 1.45, which has changed by -21.97% over the last 52 weeks, in comparison to a change of 28.14% over the same period for the S&P500. Over the past 52 weeks, CTXR has reached a high of $1.71, while it has fallen to a 52-week low of $0.60. The 50-Day Moving Average of the stock is 0.7341, while the 200-Day Moving Average is calculated to be 0.8256.
Shares Statistics:
According to the various share statistics, CTXR traded on average about 677.17K shares per day over the past 3-months and 786.32k shares per day over the past 10 days. A total of 158.86M shares are outstanding, with a floating share count of 146.79M. Insiders hold about 7.74% of the company’s shares, while institutions hold 16.96% stake in the company. Shares short for CTXR as of Mar 15, 2024 were 12.18M with a Short Ratio of 17.99, compared to 11.58M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.66% and a Short% of Float of 8.30%.
Earnings Estimates
The company has 2 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of -$0.05 and a low estimate of -$0.06, while EPS last year was -$0.07. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.21 and -$0.21 for the fiscal current year, implying an average EPS of -$0.21. EPS for the following year is $0.12, with 2 analysts recommending between $0.16 and $0.09.
Revenue Estimates
Based on 2 analysts’ estimates, the company’s revenue will be $83.59M in the next fiscal year. The high estimate is $121.3M and the low estimate is $45.89M. The average revenue growth estimate for next year is up 35.40% from the average revenue estimate for this year.
